Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H17N3.ClH |
| Molecular Weight | 287.787 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCCN(N1C=CC2=C1C=CC=C2)C3=CC=NC=C3
InChI
InChIKey=ZDFVWDHZXAGROF-UHFFFAOYSA-N
InChI=1S/C16H17N3.ClH/c1-2-12-18(15-7-10-17-11-8-15)19-13-9-14-5-3-4-6-16(14)19;/h3-11,13H,2,12H2,1H3;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C16H17N3 |
| Molecular Weight | 251.3263 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=269038 | http://adisinsight.springer.com/drugs/800001339 | https://www.ncbi.nlm.nih.gov/pubmed/9103515 | https://www.ncbi.nlm.nih.gov/pubmed/7674813
Curator's Comment: description was created based on several sources, including:
http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=269038 | http://adisinsight.springer.com/drugs/800001339 | https://www.ncbi.nlm.nih.gov/pubmed/9103515 | https://www.ncbi.nlm.nih.gov/pubmed/7674813
Besipirdine is a potential novel first-in-class oral treatment for over active bladder currently in Phase II development, with a mechanism of action clearly different from that of antimuscarinics. It was under evaluation by Aventis up to phase III for Alzheimer’s disease, involving the administration of the compound to over 1500 patients. However, this research has been discontinued. Besipirdine antagonizes alpha-2 and alpha-1 adrenoceptors and inhibits both norepinephrine and serotonin uptake. The most common adverse events were asymptomatic postural hypotension and asymptomatic bradycardia.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1907610 |
5.66 µM [Ki] | ||
Target ID: CHEMBL2093864 |
0.38 µM [Ki] | ||
Target ID: CHEMBL273 |
17.0 µM [IC50] | ||
Target ID: Voltage-dependent sodium channel (rat) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Determination of HP 749, a potential therapeutic agent for Alzheimer's disease, in plasma by high-performance liquid chromatography. | 1991 Dec 6 |
|
| HP 749 enhances calcium-independent release of [3H]norepinephrine from rat cortical slices and synaptosomes. | 1994 Oct |
|
| The pharmacokinetics and cardiovascular pharmacodynamics of HP 749 (besipirdine HCl) and metabolite P86-7480 in the conscious monkey. | 1995 Jul |
Sample Use Guides
Besipirdine inhibited [3H]-batrachotoxin binding (IC50 = 5.5 uM) in a rat brain vesicular preparation and concentration-dependently inhibited veratridine (25 uM)-stimulated increases in intracellular free sodium ([Na+]i) and calcium ([Ca2+]i) in primary cultured cortical neurones of rat. Besipirdine (30-100 uM) concentration-dependently inhibited (up to 100%) veratridine-stimulated release of [3H]-noradrenaline (NA) from rat cortical slices.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:01:07 GMT 2023
by
admin
on
Sat Dec 16 05:01:07 GMT 2023
|
| Record UNII |
2541WG0P2F
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C87053
Created by
admin on Sat Dec 16 05:01:07 GMT 2023 , Edited by admin on Sat Dec 16 05:01:07 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB00766MIG
Created by
admin on Sat Dec 16 05:01:07 GMT 2023 , Edited by admin on Sat Dec 16 05:01:07 GMT 2023
|
PRIMARY | |||
|
DD-43
Created by
admin on Sat Dec 16 05:01:07 GMT 2023 , Edited by admin on Sat Dec 16 05:01:07 GMT 2023
|
PRIMARY | |||
|
CHEMBL29835
Created by
admin on Sat Dec 16 05:01:07 GMT 2023 , Edited by admin on Sat Dec 16 05:01:07 GMT 2023
|
PRIMARY | |||
|
100000085003
Created by
admin on Sat Dec 16 05:01:07 GMT 2023 , Edited by admin on Sat Dec 16 05:01:07 GMT 2023
|
PRIMARY | |||
|
DTXSID20156811
Created by
admin on Sat Dec 16 05:01:07 GMT 2023 , Edited by admin on Sat Dec 16 05:01:07 GMT 2023
|
PRIMARY | |||
|
m1024
Created by
admin on Sat Dec 16 05:01:07 GMT 2023 , Edited by admin on Sat Dec 16 05:01:07 GMT 2023
|
PRIMARY | Merck Index | ||
|
C90630
Created by
admin on Sat Dec 16 05:01:07 GMT 2023 , Edited by admin on Sat Dec 16 05:01:07 GMT 2023
|
PRIMARY | |||
|
68742
Created by
admin on Sat Dec 16 05:01:07 GMT 2023 , Edited by admin on Sat Dec 16 05:01:07 GMT 2023
|
PRIMARY | |||
|
2541WG0P2F
Created by
admin on Sat Dec 16 05:01:07 GMT 2023 , Edited by admin on Sat Dec 16 05:01:07 GMT 2023
|
PRIMARY | |||
|
130953-69-4
Created by
admin on Sat Dec 16 05:01:07 GMT 2023 , Edited by admin on Sat Dec 16 05:01:07 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |